Interview with Michael Adridge

Hi guys

For anyone interested ......



Much of it is info that most followers of HXL would be aware of ...but its nicely paced
and a good "refresher "

Interview also discusses milestones for 2022

>  Hoping to secure a  corporate partner  - ref future licensing into Japan
>  Hoping to release Phase 2B clinical trial results  ( 100 + patients )  
>  Hoping to get headway in US with FDA approval for trials
> They will need more funds to do the FDA trial etc  -  later in 2022 -2023

Most people get a bit scared off at the thought of more funds being required , however
the pieces seem to be all coming to together for HXL ..... and its quite probably that as
their solution for Toe nail fungus gets more "De Risked " so to speak ...... perceived valuations of HXL  
may well be substantially higher than current .